O	0	13	Postoperative
O	14	22	adjuvant
O	23	26	use
O	27	29	of
B-intervention	30	38	carmofur
O	39	42	for
O	43	48	early
O	49	55	breast
O	56	62	cancer
O	62	63	.

O	64	67	The
O	68	76	efficacy
O	77	79	of
O	80	84	oral
O	85	101	fluoropyrimidine
O	102	110	carmofur
O	111	114	was
O	115	124	evaluated
O	125	128	for
O	129	137	adjuvant
O	138	141	use
O	142	145	for
O	146	152	breast
O	153	159	cancer
O	159	160	.

B-total-participants	161	164	150
B-eligibility	165	173	patients
I-eligibility	174	178	with
I-eligibility	179	185	breast
I-eligibility	186	192	cancer
I-eligibility	193	195	of
I-eligibility	196	200	T0N1
I-eligibility	200	201	,
I-eligibility	202	204	T1
I-eligibility	204	205	,
I-eligibility	206	208	N1
I-eligibility	208	209	,
I-eligibility	210	214	T2N0
I-eligibility	214	215	,
I-eligibility	216	219	and
I-eligibility	220	224	T2N1
O	225	229	were
O	230	240	randomized
O	241	243	to
B-intervention-participants	244	247	100
O	248	251	for
O	252	260	carmofur
O	261	264	and
B-control-participants	265	267	50
O	268	271	for
B-control	272	282	carboquone
O	282	283	.

O	284	288	Both
O	289	294	drugs
O	295	299	were
O	300	312	administered
O	313	325	continuously
O	326	329	for
O	330	332	28
O	333	337	days
O	338	348	cyclically
O	349	352	for
O	353	354	5
O	355	360	years
O	361	365	with
O	366	367	a
O	368	377	cessation
O	378	384	period
O	385	387	of
O	388	390	28
O	391	395	days
O	396	399	for
O	400	408	carmofur
O	409	412	and
O	413	415	56
O	416	420	days
O	421	424	for
O	425	435	carboquone
O	435	436	.

B-outcome	437	444	Overall
I-outcome	445	453	survival
O	454	463	excluding
O	464	467	non
O	467	468	-
O	468	474	breast
O	475	481	cancer
O	482	487	death
O	488	491	was
B-iv-bin-percent	492	494	90
I-iv-bin-percent	494	495	%
O	496	499	for
O	500	503	the
O	504	512	carmofur
O	513	518	group
O	519	522	and
B-cv-bin-percent	523	525	88
I-cv-bin-percent	525	526	%
O	527	530	for
O	531	534	the
O	535	545	carboquone
O	546	551	group
O	551	552	,
O	553	561	adjusted
O	562	564	by
O	565	568	Cox
O	568	569	'
O	569	570	s
O	571	581	regression
O	582	590	analysis
O	590	591	.

O	592	602	Difference
O	603	605	in
O	606	610	drug
O	611	616	never
O	617	625	affected
O	626	634	survival
O	634	635	.

B-outcome	636	645	Leukocyte
I-outcome	646	651	count
O	652	655	was
O	656	665	decreased
O	666	668	in
O	669	672	the
O	673	683	carboquone
O	684	689	group
O	689	690	,
O	691	694	but
O	695	697	no
O	698	704	change
O	705	707	in
O	708	713	serum
O	714	726	transaminase
O	727	730	was
O	731	736	found
O	737	739	in
O	740	746	either
O	747	752	group
O	752	753	.

O	754	757	Ten
O	758	766	patients
O	766	767	,
B-iv-bin-abs	768	769	5
O	770	773	for
O	774	782	carmofur
O	783	786	and
B-cv-bin-abs	787	788	5
O	789	792	for
O	793	803	carboquone
O	803	804	,
O	805	813	suffered
O	814	818	from
B-outcome	819	825	second
I-outcome	826	836	malignancy
O	836	837	,
O	838	842	more
O	843	847	than
O	848	856	expected
O	857	859	in
O	860	863	the
O	864	870	normal
O	871	881	population
O	881	882	,
O	883	886	but
O	887	897	difference
O	898	900	in
O	901	904	the
O	905	915	cumulative
O	916	920	rate
O	921	923	of
O	924	928	each
O	929	934	group
O	935	938	was
O	939	942	not
O	943	954	significant
O	954	955	.

O	956	964	Adjuvant
O	965	968	use
O	969	971	of
O	972	980	carmofur
O	981	983	as
O	984	988	well
O	989	991	as
O	992	1002	carboquone
O	1003	1005	is
O	1006	1016	beneficial
O	1017	1020	for
O	1021	1026	early
O	1027	1033	breast
O	1034	1040	cancer
O	1040	1041	.
